| 张磊 李曦哲 顾红兵 叶一舟△.心肌梗死细胞治疗的临床试验进展[J].,2016,16(9):1753-1755 |
| 心肌梗死细胞治疗的临床试验进展 |
| Clinical Trial Progress of Cell therapy for Myocardial Infarction |
| |
| DOI： |
| 中文关键词: 心肌梗死 干细胞移植 细胞种类 临床试验 |
| 英文关键词: Myocardial infarction Stemcell transplantation Cell type Clinical trial |
| 基金项目: |
|
| 摘要点击次数: 695 |
| 全文下载次数: 0 |
| 中文摘要: |
| 干细胞移植治疗心肌梗死已有10 余年历史，目的在于增加支架介入或冠脉搭桥治疗基础上的获益。细胞种类的选择是决
定疗效的关键，大致可分为" 第一代" 和" 第二代"干细胞。" 第一代" 是谱系非选择性干细胞，分自体和异体，早期阳性结果居
多，近年多为中性结果。" 第二代"是纯化干细胞，通过细胞表面标记分选出特定细胞谱系，即心脏干细胞，进行定向分化，在II期
临床试验中展现获益。另外，近来诱导多能干细胞iPSC成为研究热点。目前干细胞直接心肌再生的证据很少，越来越多的研究肯
定其旁分泌作用。 |
| 英文摘要: |
| Cell therapy for myocardial infarction had a history of ten years, aimed at additional benefit of traditional treatment
such as coronary artery intervention or coronary artery bypass graft. It was the cell type that determined curative effect, which was roughly
divided into two categories, the first and second generation of stemcells. The first generation was non-selective cell lineage, including autograft
and allograft, the early positive results in the majority but more than to neutral results in recent years. The second generation was
purified stem cell, sorting specific cell lineage, cardiac stem cell, for directional differentiation through cell surface markers and showed
benefit in phase II clinical trials. Besides, induced pluripotent stemcell had become the research hotspot. Currently, the evidence of myocardial
direct regeneration was very little, more and more research affirmed its paracrine function. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
